SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Jones R, Sawleshwarkar S, Michailidis C et al. Impact of antiretroviral choice on hypercholesterolemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6: 396402.
  • 3
    Morse CG, Kovacs JA. Metabolical and skeletal complications of HIV infection: the price of success. JAMA 2006; 296: 844854.
  • 4
    Monier PL, Wilcox R. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1 infected adults. Am J Med Science 2004; 328: 4856.
  • 5
    Martinez E, Domingo P, Galindo MJ et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir/ritonavir. Clin Infect Dis 2004; 38: 10171023.
  • 6
    Solorzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G et al. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 2006; 37: 129132.
  • 7
    Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003; 37 (Suppl. 2): S85S90.
  • 8
    The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 9
    Joung J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585591.
  • 10
    Bergersen BM. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs 2006; 66: 19711987.
  • 11
    De Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4: 213222.
  • 12
    Kwong GS, Ghani AC, Rode RA et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20: 19411950.
  • 13
    Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257262.
  • 14
    Wang X, Chai H, Yao Q et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J AIDS 2007; 44: 493499.
  • 15
    Mercié P, Thiébaut R, Aurillac-Lavignolle V et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6: 380387.
  • 16
    Law M, Friis Møller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the data collection on adverse events of Anti-HIV drugs (DAD) study. HIV Med 2003; 4: 110.
  • 17
    The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Medicine 2007; 356: 17231735.
  • 18
    Fitch KV, Anderson EJ, Hubbard JL et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006; 20: 18431850.
  • 19
    Sabin CA, Weber R, Fontas E et al. Underutilization of recommended interventions for prevention of cardiovascular (CV) disease in HIV-infected patients with established CV disease or diabetes. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007 [Abstract 816].
  • 20
    Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005; 65: 23092336.
  • 21
    Möbius U, Lubach-Ruitman M, Castro-Frenzel B et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J AIDS 2005; 39: 174180.
  • 22
    Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711718.
  • 23
    Busti AJ, Bedimo R, Margolis D, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir/ritonavir (ATV/RTV): a prospective study using hyperinsulinemic, euglycaemic clamp testing. 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, USA, 24–26 September 2006 [Abstract 57].
  • 24
    Negredo E, Echeverria P, Puig J et al. Lipid profile using the new protease inhibitors in antiretroviral treated HIV-infected patients. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006 [Abstract P94].
  • 25
    Keiser P, Mc Grath S, Reynolds L et al. Changes in lipid profiles in treatment-experienced patients switched to atazanavir-based antiretroviral therapy: results from the atazanavir expanded access program (EAP). XVI International AIDS Conference, Toronto, 13–18 August 2006 [Abstract WEPE0163].
  • 26
    Noor M, Parker RA, O'Mara E et al. The effects of HIV protease inhibitor atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative adults. AIDS 2004; 18: 21372144.
  • 27
    Gatell J, Salmon-Ceron D, Lazzarin A et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007; 44: 14841492.
  • 28
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.
  • 29
    Llibre JM, Domingo P, Palacios R et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2007; 20: 14071414.
  • 30
    Viganò A, Aldovrandi GM, Giacomet V et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther 2005; 10: 917924.
  • 31
    Ferrario M, Chiodini P, Chambless LE et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 2005; 34: 413421.
  • 32
    Giavarina D, Barzon E, Cigolini M et al. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. Nutr Metab Cardiovas Dis 2007; 17: 311318.
  • 33
    Friis Møller N, Thiébaut R, Reiss P et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D:A:D risk equation. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. [Abstract 808].